

January 31, 2014

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1, G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,


Subject: Amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited.

This is to inform you that the Board of Directors of Glenmark Pharmaceuticals Ltd. ("GPL"), in their meeting held today, have approved a proposal to merge its subsidiaries i.e. Glenmark Generics Ltd. ("GGL") and Glenmark Access Ltd. ("GAL") with GPL.

The merger will be effected through a court approved Scheme of Amalgamation under Sections 391 to 394 and other applicable provisions of the Companies Act, 1956 ("Scheme"). As on date 99.33 % of the share capital of GGL is being held by GPL (including 1.19% being held by GAL, a wholly owned subsidiary of GPL). Per the Scheme, the remaining shareholders holding 0.67 % (10,16,741 equity shares) of the share capital of GGL will be issued shares of GPL at a swap ratio which has been determined as 4 shares of GPL of Re. 1 each for every 5 shares of Rs. 10 each held by the shareholders of GGL.

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, HDO-Corporate Building, Wing A, B D Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai 400 099
T : 91 22 4018 9999 F : 91 22 4018 9986 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026.